Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Optical imaging systems that utilize multispectral imaging can reduce signal degradation caused by autofluorescence while adding enhanced multiplexing capabilities. The super resolution microscopy SPDM revealed autofluorescent cellular objects which are not detectable under conventional fluorescence imaging conditions.
=== Paradoxical effects === Paradoxical reactions, such as increased seizures in epileptics, aggression, violence, impulsivity, irritability and suicidal behavior sometimes occur. These reactions have been explained as consequences of disinhibition and the subsequent loss of control over socially unacceptable behavior. Paradoxical reactions are rare in the general population, with an incidence rate below 1% and similar to placebo. However, they occur with greater frequency in recreational abusers, individuals with borderline personality disorder, children, and patients on high-dosage regimes. In these groups, impulse control problems are perhaps the most important risk factor for disinhibition; learning disabilities and neurological disorders are also significant risks. Most reports of disinhibition involve high doses of high-potency benzodiazepines. Paradoxical effects may also appear after chronic use of benzodiazepines.
Meanwhile, Duterte's ICC withdrawal was challenged before the Supreme Court by three petitions filed by the Philippine Coalition for the ICC, the Integrated Bar of the Philippines, and opposition senators; though the Court in March 2021 ultimately dismissed all three cases on the grounds that the petitioners were unable to establish legal standing to challenge the ICC withdrawal, the court ruled that the president has no "unbridled authority" to withdraw from treaties. The ICC, on September 16, 2021, eventually authorized a formal investigation into the war on drugs in the Philippines, focusing on crimes committed between 2016 and March 2019. In response, the Philippine government in November 2021 requested a deferral of the probe, which was suspended by the ICC to assess the request. Four days before Duterte left office, however, ICC prosecutor Karim Ahmad Khan requested the pre-trial chamber of the ICC to immediately resume the investigation after concluding that the deferral request was "not warranted". The succeeding Marcos administration initially declined to allow any ICC probe in the country due to sovereignty issues; however, due to tensions between the Duterte and Marcos political families, the Marcos administration is seen as increasingly open to cooperating with the ICC. Duterte stated he remained unfazed at the threat of arrest, saying he would rather "die first" before facing a foreign court. Salvador Panelo, who served as Duterte's chief legal counsel, alleged that Duterte's political opponents were using the ICC as a "political and propaganda apparatus".
== Early career == After university, he joined the New Statesman, where he worked between 2001 and 2003, and then wrote two columns a week for The Independent. At the 2003 Press Gazette Awards, he won Young Journalist of the Year. A play by Hari, Going Down in History, was performed at the Garage Theatre in Edinburgh, and his book God Save the Queen? was published by Icon Books in 2002. Hari supported the Iraq War. In 2009, he was named by The Daily Telegraph as one of the most influential people on the left in Britain.
== Exploration of L-Threonine for Tuberculosis == With multidrug-resistant Mycobacterium tuberculosis (TB) remaining a public health crisis with a total of 1.25 million people dead worldwide from TB in 2023 alone, new treatment strategies for TB are critical. TB is an airborne infection, spread via inhalation of airborne droplets that can remain suspended in the air for several hours, and can either be killed, remain in a latent stage, or become active. One previous paper researched the inhibitory effects of the downstream product L-threonine on the homoserine kinase (HSK) pathway in Escherichia coli. They found that the HSK pathway can be successfully inhibited via L-threonine since the pathway acts as a negative feedback loop, becoming inhibited once enough of the product is formed. Investigation of this pathway in TB may yield new insights into potential drug targets. Inhibiting the fatty acid synthesis pathway as well could serve as a potential drug target since this pathway is responsible for synthesizing mycolic acids, components necessary for formation of TB's cell walls. Coupling of the amino acid L-threonine with a common TB drug that inhibits fatty acid synthesis, like ethionamide, could yield a new treatment strategy for tuberculosis.
Sources: en.wikipedia.org
==== Removal of Carlos Gallardo Gómez ==== On 21 December 2021, with 70 votes in favor, Congress forced Carlos Gallardo Gómez to resign as Minister of Education. Congress accused Carlos Gallardo Gómez of having ties to the Shining Path and leaking the answers of the 2021 teacher appointment exam. Gómez was replaced with Rosendo Serna.
1. A mobilization of intracellular Ca2+ ions is closely connected with a biological activity of sarafotoxins; 2. The blockers specific to Ca2+ channels, such as verapamil or ninodipine, have no effect on binding capability of 125I-SRTX-b; 3. The hydrolysis of phosphoinositides is induced by binding of SRTXs. Above characteristics suggest that sarafotoxins (and endothelins) use the phosphoinositide signal transduction pathway via specific receptors coupled to G protein, which seems to activate type C and D phospholipases. However, distinct and widespread subtypes of glycosylated receptors are recognized functionally by SRTXs and ETs. As all of the three isoforms of endothelins and sarafotoxins interplay with the same affinity, ETB-R appears less selective than ETA-R. Nonetheless, the variable tissue distribution of the endothelin-binding sites, and the different biological effects demonstrated within different organs, indicate the possibility of an existence of other endothelin/sarafotoxin subtypes of receptors. Therefore, the ability of the Egyptian mongoose to resist very high concentrations of SRTX-b may be due to presence of an additional family of binding sites, located in the cardiovascular tissue, differentiating ET-1 and SRTX-b.
In Peranakan cuisine across Maritime Southeast Asia, fish maw is a traditional Chinese New Year food. The ingredient features particularly in hee pio soup (a.k.a. hu pioh t'ng), a clear soup of fish maw paired with a varied selection of other vegetables and proteins. In Thailand, a Thai cuisine fish maw dish is kaeng tai pla (Thai: แกงไตปลา), a Southern Thai fishermen dish featuring tai pla, fermented fish maw. Krapaw pla is a Thai-Chinese fish maw stew in a red braise. Vietnamese cuisine does not typically feature fish maw, but fish maw is sometimes featured in xúp cua, a Vietnamese crab soup (súp cua bong bóng cá).
== Diagnosis == The diagnosis of GPS is often difficult, as numerous other diseases can cause the various manifestations of the condition, and the condition itself is rare. The most accurate means of achieving the diagnosis is testing the affected tissues by means of a biopsy, especially the kidney, as it is the best-studied organ for obtaining a sample for the presence of anti-GBM antibodies. On top of the anti-GBM antibodies implicated in the disease, about one in three of those affected also has cytoplasmic antineutrophilic antibodies in their bloodstream, which often precedes the anti-GBM antibodies by a few months or even years. The later the disease is diagnosed, the worse the outcome is for the affected person. In addition, if there is substantial suspicion of the disease, serologic testing for the ELISA assay is usually done by looking for the alpha3 NC1 domain area of collagen IV to avoid false positives.
=== Impaired neutrophil migration and tumor necrosis factor- Alpha === Impaired neutrophil migration (caused by genetic defects, infections, and the aging process) causes increased macrophage activity that can lead to granuloma formation, a hallmark of NL. Furthermore, TNF-α is a pro-inflammatory cytokine that's activated by macrophages, and it plays a critical role in granuloma formation.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.